| 21317208 |
Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide
Prasad, G,
Sottero, T,
Yang, X,
Mueller, S,
James, CD,
Weiss, WA,
Polley, MY,
Ozawa, T,
Berger, MS,
Aftab, DT,
Prados, MD,
Haas-Kogan, DA
|
Neuro-oncology |
2011 |
| 8657148 |
Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction
Wymann, MP,
Bulgarelli-Leva, G,
Zvelebil, MJ,
Pirola, L,
Vanhaesebroeck, B,
Waterfield, MD,
Panayotou, G
|
Mol. Cell. Biol. |
1996 |
| 19411071 |
Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941
Junttila, TT,
Akita, RW,
Parsons, K,
Fields, C,
Lewis Phillips, GD,
Friedman, LS,
Sampath, D,
Sliwkowski, MX
|
Cancer Cell |
2009 |
| 19644473 |
Targeting the phosphoinositide 3-kinase pathway in cancer
Liu, P,
Cheng, H,
Roberts, TM,
Zhao, JJ
|
Nat Rev Drug Discov |
2009 |
| 22188813 |
Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor
Maira, SM,
Pecchi, S,
Huang, A,
Burger, M,
Knapp, M,
Sterker, D,
Schnell, C,
Guthy, D,
Nagel, T,
Wiesmann, M,
Brachmann, S,
Fritsch, C,
Dorsch, M,
Chène, P,
Shoemaker, K,
De Pover, A,
Menezes, D,
Martiny-Baron, G,
Fabbro, D,
Wilson, CJ,
Schlegel, R,
Hofmann, F,
García-Echeverría, C,
Sellers, WR,
Voliva, CF
|
Mol. Cancer Ther. |
2012 |
| 21976531 |
Novel phosphoinositide 3-kinase/mTOR dual inhibitor, NVP-BGT226, displays potent growth-inhibitory activity against human head and neck cancer cells in vitro and in vivo
Chang, KY,
Tsai, SY,
Wu, CM,
Yen, CJ,
Chuang, BF,
Chang, JY
|
Clin. Cancer Res. |
2011 |
| 18606717 |
Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
Maira, SM,
Stauffer, F,
Brueggen, J,
Furet, P,
Schnell, C,
Fritsch, C,
Brachmann, S,
Chène, P,
De Pover, A,
Schoemaker, K,
Fabbro, D,
Gabriel, D,
Simonen, M,
Murphy, L,
Finan, P,
Sellers, W,
García-Echeverría, C
|
Mol. Cancer Ther. |
2008 |
| 18829560 |
NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations
Serra, V,
Markman, B,
Scaltriti, M,
Eichhorn, PJ,
Valero, V,
Guzman, M,
Botero, ML,
Llonch, E,
Atzori, F,
Di Cosimo, S,
Maira, M,
Garcia-Echeverria, C,
Parra, JL,
Arribas, J,
Baselga, J
|
Cancer Res. |
2008 |
| 18754654 |
The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer
Folkes, AJ,
Ahmadi, K,
Alderton, WK,
Alix, S,
Baker, SJ,
Box, G,
Chuckowree, IS,
Clarke, PA,
Depledge, P,
Eccles, SA,
Friedman, LS,
Hayes, A,
Hancox, TC,
Kugendradas, A,
Lensun, L,
Moore, P,
Olivero, AG,
Pang, J,
Patel, S,
Pergl-Wilson, GH,
Raynaud, FI,
Robson, A,
Saghir, N,
Salphati, L,
Sohal, S,
Ultsch, MH,
Valenti, M,
Wallweber, HJ,
Wan, NC,
Wiesmann, C,
Workman, P,
Zhyvoloup, A,
Zvelebil, MJ,
Shuttleworth, SJ
|
J. Med. Chem. |
2008 |
| 21368164 |
Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors
Chakrabarty, A,
Sánchez, V,
Kuba, MG,
Rinehart, C,
Arteaga, CL
|
Proc. Natl. Acad. Sci. U.S.A. |
2012 |
